Cynata Therapeutics, a stem cell and regenerative medicine company listed on the Australian stock exchange (ASX: CYP), released major news today that the Japanese Patent Office will grant a patent for its unique Cymerus™ MSC technology.
Titled “Generation of Clonal Mesenchymal Progenitors and Mesenchymal Stem Cell Lines Under Serum-free Conditions,” the patent covers a proprietary method for deriving MSCs from pluripotent stem cells, to which Cynata Therapeutics with commercial rights in Japan through 2031.
Cynata’s Cymerus technology utilizes iPSCs originating from an adult donor as the starting material for generating mesenchymoangioblast (MCAs), and subsequently, for differentiating the cells into mesenchymal stem cells (MSCs). MSCs are currently being explored in nearly 500 clinical trials worldwide, but robust technologies for scaling and standardizing the manufacture of MSCs are scare.
Fortunately, Cynata’s breakthrough technology allows it to produce MSCs in unlimited quantities, in uniform batches, from a single donor, and at low cost.
Importantly, the Cymerus platform also positions Cynata to be the first company worldwide to conduct a clinical trial using an allogeneic iPSC-derived MSC product, an enormous achievement for Cynata and its shareholders.
Strategic Importance of Cynata’s Japanese Patent Announcement
Cynata’s announcement that the Japanese Patent and Trademark Office has decided to grant a patent covering aspects of its proprietary Cymerus™ MSC manufacturing technology is particularly significant, because Cynata recently entered into a Letter of Intent (LOI) with Regience K.K. for a strategic alliance within Japan and potentially other Asian countries.
Japan is also one of the world’s leading markets for regenerative medicine and stem cells.
Therefore, this patent announcement positions Cynata to benefit from this and other strategic alliances it is now pursuing.
Cynata has also signed a recent Letter of Intent (LOI) with the German company, apceth GmbH & Co. KG, a well-funded European group whose major shareholders are the Strungmann family.
Future announcements of strategic partnerships for licensing of the Cymerus technology are also expected, because Cynata’s technology solves a major hurdle that has restricted the viability of other MSC clinical trials. This hurtle is how to economically produce consistent, clinical-grade MSCs in unlimited quantities.
Cynata Therapeutics is a promising company for regenerative medicine investors to watch, because the company’s ability to produce consistent, scalable MSCs will substantially expand therapeutic applications for the cell type. Its ability to partner with companies in Japan and worldwide also gives it a unique value proposition within the marketplace.
Click here to learn more about Cynata’s announcement that it will receive exclusive rights to a Japanese patent covering its proprietary method for deriving MSCs from pluripotent stem cells.
Want to be better informed than your competition? Get future stem cell industry updates.
BioInformant is the first and only market research firm to specialize exclusively in the stem cell industry. BioInformant research has been cited by major news outlets that include the Wall Street Journal, Nature Biotechnology, Medical Ethics, Vogue Magazine, and more. Serving Fortune 500 leaders that include GE Healthcare, Pfizer, and Goldman Sachs, BioInformant is your global leader in stem cell industry data.